ATE478872T1 - Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung - Google Patents

Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung

Info

Publication number: ATE478872T1
Authority: AT; Austria
Prior art keywords: alkyl; group; cycloalkyl; optionally substituted; alkenyl
Prior art date: 2002-03-28

Application number

AT02007163T

Other languages

English (en)

Inventor

Daniela Moravcova

Libor Havlicek

Vladimir Krystof

Rene Lenobel

Miroslav Strnad

Original Assignee

Ustav Ex Botan Av Cr V V I I O

Univerzita Palackeho V Olomouc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-28

Filing date

2002-03-28

Publication date

2010-09-15

2002-03-28 Application filed by Ustav Ex Botan Av Cr V V I I O, Univerzita Palackeho V Olomouc filed Critical Ustav Ex Botan Av Cr V V I I O

2010-09-15 Application granted granted Critical

2010-09-15 Publication of ATE478872T1 publication Critical patent/ATE478872T1/de

Links

230000001225 therapeutic effect Effects 0.000 title 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
125000006193 alkinyl group Chemical group 0.000 abstract 5
125000000753 cycloalkyl group Chemical group 0.000 abstract 5
125000006727 (C1-C6) alkenyl group Chemical group 0.000 abstract 3
125000003118 aryl group Chemical group 0.000 abstract 3
-1 cycloheteroalkyl Chemical group 0.000 abstract 3
125000003342 alkenyl group Chemical group 0.000 abstract 2
125000000217 alkyl group Chemical group 0.000 abstract 2
125000003710 aryl alkyl group Chemical group 0.000 abstract 2
229910052736 halogen Inorganic materials 0.000 abstract 2
125000005843 halogen group Chemical group 0.000 abstract 2
125000001072 heteroaryl group Chemical group 0.000 abstract 2
125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
125000000623 heterocyclic group Chemical group 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
125000003545 alkoxy group Chemical group 0.000 abstract 1
125000003282 alkyl amino group Chemical group 0.000 abstract 1
125000002877 alkyl aryl group Chemical group 0.000 abstract 1
125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
125000004404 heteroalkyl group Chemical group 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000000547 substituted alkyl group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Neurology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Oncology (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Transplantation (AREA)
Obesity (AREA)
Virology (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Tropical Medicine & Parasitology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)

AT02007163T 2002-03-28 2002-03-28 Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung ATE478872T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP02007163A EP1348707B1 (de)	2002-03-28	2002-03-28	Pyrazolo[4,3-d]pyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung

Publications (1)

Publication Number	Publication Date
ATE478872T1 true ATE478872T1 (de)	2010-09-15

Family

ID=27798825

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02007163T ATE478872T1 (de)	2002-03-28	2002-03-28	Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung

Country Status (9)

Country	Link
US (1)	US7745450B2 (de)
EP (1)	EP1348707B1 (de)
JP (1)	JP2005527565A (de)
AT (1)	ATE478872T1 (de)
AU (1)	AU2003226731B2 (de)
CA (1)	CA2480409C (de)
DE (1)	DE60237425D1 (de)
DK (1)	DK1348707T3 (de)
WO (1)	WO2003082872A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050154046A1 (en) *	2004-01-12	2005-07-14	Longgui Wang	Methods of treating an inflammatory-related disease
OA13050A (en)	2003-04-29	2006-11-10	Pfizer Ltd	5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.
CA2532965C (en)	2003-07-22	2013-05-14	Astex Therapeutics Limited	3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
US7572799B2 (en)	2003-11-24	2009-08-11	Pfizer Inc	Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
GB0327319D0 (en) *	2003-11-24	2003-12-24	Pfizer Ltd	Novel pharmaceuticals
GB0327323D0 (en) *	2003-11-24	2003-12-31	Pfizer Ltd	Novel pharmaceuticals
AU2004309420B2 (en) *	2003-12-23	2008-10-30	Novartis Ag	Bicyclic heterocyclic p-38 kinase inhibitors
CA2562251C (en)	2004-04-07	2009-04-28	Pfizer Inc.	Pyrazolo'4,3-d pyrimidines
CA2569016C (en) *	2004-06-02	2012-11-27	Takeda Pharmaceutical Company Limited	Fused heterocyclic compound
ES2368930T3 (es)	2004-09-06	2011-11-23	Bayer Pharma Aktiengesellschaft	Pirazolopirimidinas como inhibidores de proteína cinasa b (akt).
AR054425A1 (es)	2005-01-21	2007-06-27	Astex Therapeutics Ltd	Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en)	2005-01-21	2013-03-26	Astex Therapeutics Limited	Combinations of pyrazole kinase inhibitors
RU2425677C2 (ru) *	2005-01-21	2011-08-10	Астекс Терапьютикс Лимитед	Соединения, предназначенные для использования в фармацевтике
CA2608018C (en) *	2005-05-12	2010-07-13	Pfizer Inc.	Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
US7932257B2 (en)	2005-07-22	2011-04-26	Sunesis Pharmaceuticals, Inc.	Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors
NL2000291C2 (nl)	2005-11-10	2009-02-17	Pfizer Prod Inc	1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
FR2899107B1 (fr)	2006-03-30	2008-06-13	Neurokin Entpr Unipersonnelle	Utilisation de la (s)-roscovitine pour la fabrication d'un medicament
US20100004238A1 (en)	2006-12-12	2010-01-07	Takeda Pharmaceutical Company Limited	Fused heterocyclic compound
US20090099195A1 (en) *	2007-05-08	2009-04-16	Astrazeneca Ab	Therapeutic Compounds 570
UA103195C2 (uk)	2008-08-11	2013-09-25	Глаксосмитклайн Ллк	Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
MX2011004680A (es)	2008-11-06	2011-05-25	Astrazeneca Ab	Moduladores de beta amiloide.
CZ2009358A3 (cs) *	2009-06-03	2010-12-15	C3 Bio Gmbh	5,7-Disubstituované 3-isopropylpyrazolo[4,3-d]pyrimidiny pro použití jako lécivo a farmaceutické prípravky tyto látky obsahující
CZ302711B6 (cs) *	2009-06-03	2011-09-14	Univerzita Palackého v Olomouci	Substituované deriváty 6-(2-hydroxybenzylamino)purinu, jejich použití jako léciva a farmaceutické prípravky tyto slouceniny obsahující
AP2013007253A0 (en) *	2011-04-21	2013-11-30	Origenis Gmbh	Pyrazolo [4,3-D] pyrimidines useful as kinase inhibitors
HRP20181667T1 (hr)	2011-07-22	2018-12-14	Glaxosmithkline Llc	Pripravak
AR090650A1 (es) *	2012-04-12	2014-11-26	Alcon Res Ltd	Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo
EA026354B1 (ru)	2012-08-24	2017-03-31	ГЛАКСОСМИТКЛАЙН ЭлЭлСи	Пиразолопиримидиновые соединения
WO2014060112A1 (en) *	2012-10-19	2014-04-24	Origenis Gmbh	Pyrazolo[4,3-d]pyrimidines as kinase inhibitors
BR112015011439A2 (pt)	2012-11-20	2017-07-11	Glaxosmithkline Llc	composto, composição farmacêutica, composição de vacina, e, uso de um composto
EA028480B1 (ru)	2012-11-20	2017-11-30	ГЛАКСОСМИТКЛАЙН ЭлЭлСи	Новые соединения
AU2013348217B2 (en)	2012-11-20	2016-10-06	Glaxosmithkline Llc	Novel compounds
CN103405439B (zh) *	2013-08-02	2014-12-31	上海市第十人民医院	嘧啶类化合物在制备真菌药物的应用
EP3271017A4 (de) *	2015-03-16	2018-11-14	Monash University	Behandlung von hauterkrankungen
CZ307147B6 (cs) *	2015-05-14	2018-02-07	Ústav experimentální botaniky AV ČR, v. v. i.	5-Substituované 7-[4-(2-pyridyl)fenylmethylamino]-3-isopropylpyrazolo[4,3-d]pyrimidiny, jejich použití jako léčiva, a farmaceutické přípravky
RU2019112740A (ru)	2016-09-30	2020-11-02	АСАНА БАЙОСАЙЕНСИЗ, ЭлЭлСи	P2x3 и/или p2x2/3 соединения и способы
CZ308484B6 (cs)	2018-02-05	2020-09-16	Univerzita PalackĂ©ho v Olomouci	5-Alkylthio-7-[(4-arylbenzyl)amino]-1(2)H-pyrazolo[4,3-d]pyrimidiny pro léčení lymfomů
EP3797776B1 (de) *	2019-09-30	2025-07-23	Universitätsmedizin Mainz	Cdk4/6-hemmer zur behandlung von psoriasis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3988338A (en) *	1974-04-24	1976-10-26	Wisconsin Alumni Research Foundation	4-Substituted amino-2-substituted thio-pyrrolo-[2,3-d]pyrimidine derivatives
GB9013750D0 (en) *	1990-06-20	1990-08-08	Pfizer Ltd	Therapeutic agents
US5276143A (en)	1990-12-21	1994-01-04	E. I. Du Pont De Nemours And Company	Dideoxyfructonucleosides and deoxyfructonucleotides
US5801015A (en)	1995-06-05	1998-09-01	Mitotix, Inc.	Nucleic acid encoding a Candida cell cycle regulatory protein, TYP1 polypeptide
US6200980B1 (en)	1995-06-07	2001-03-13	Cell Pathways, Inc.	Method of treating a patient having precancerous lesions with phenyl purinone derivatives
PT778277E (pt) *	1995-12-08	2003-11-28	Pfizer	Derivados heterociclicos substituidos como antagonistas do crf
JP3621706B2 (ja) *	1996-08-28	2005-02-16	ファイザー・インク	置換された６，５―ヘテロ―二環式誘導体
US5723608A (en) *	1996-12-31	1998-03-03	Neurogen Corporation	3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
US6723719B1 (en) *	1997-04-25	2004-04-20	Pfizer Inc	Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′—monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction
US5985848A (en) *	1997-10-14	1999-11-16	Albert Einstein College Of Medicine Of Yeshiva University	Inhibitors of nucleoside metabolism
RS50011B (sr) *	1998-04-20	2008-09-29	Pfizer Inc.,	Derivati piridin-3-karboksilne kiseline i njihova upotreba kao intermedijera
BR9915532A (pt) *	1998-10-23	2001-08-14	Pfizer	Inibidores de cgmp pde5 de pirazolopirimidinona para tratamento da disfunção sexual
WO2001019827A1 (en) *	1999-09-13	2001-03-22	Cipla Ltd.	A novel process for the synthesis of sildenafil citrate
ES2272297T3 (es) *	1999-10-12	2007-05-01	Lilly Icos Llc	Medicamento destinado al tratamiento de neuropatias.
DE10060388A1 (de) *	2000-12-05	2002-06-06	Merck Patent Gmbh	Verwendung von Pyrazolo [4,3-d]pyrimidinen
EP1343506A1 (de) *	2000-12-19	2003-09-17	MERCK PATENT GmbH	Pharmazeutische formulierung enthaltend pyrazolo 4,3-d]pyrimidine und antithrombotica, calcium-antagonisten, prostaglandine oder prostaglandinderivate
GB0106661D0 (en) *	2001-03-16	2001-05-09	Pfizer Ltd	Pharmaceutically active compounds
US20030195205A1 (en) *	2001-11-02	2003-10-16	Pfizer Inc.	PDE9 inhibitors for treating cardiovascular disorders
JP2005508978A (ja) *	2001-11-02	2005-04-07	ファイザー・プロダクツ・インク	Ｐｄｅ９阻害薬によるインスリン抵抗性症候群及び２型糖尿病の治療

2002
- 2002-03-28 AT AT02007163T patent/ATE478872T1/de not_active IP Right Cessation
- 2002-03-28 EP EP02007163A patent/EP1348707B1/de not_active Expired - Lifetime
- 2002-03-28 DK DK02007163.5T patent/DK1348707T3/da active
- 2002-03-28 DE DE60237425T patent/DE60237425D1/de not_active Expired - Lifetime
2003
- 2003-03-27 CA CA2480409A patent/CA2480409C/en not_active Expired - Fee Related
- 2003-03-27 WO PCT/EP2003/003207 patent/WO2003082872A1/en not_active Ceased
- 2003-03-27 AU AU2003226731A patent/AU2003226731B2/en not_active Ceased
- 2003-03-27 JP JP2003580337A patent/JP2005527565A/ja active Pending
2004
- 2004-09-28 US US10/952,087 patent/US7745450B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2480409A1 (en)	2003-10-09
CA2480409C (en)	2010-06-22
DK1348707T3 (da)	2010-12-13
AU2003226731A1 (en)	2003-10-13
DE60237425D1 (de)	2010-10-07
US7745450B2 (en)	2010-06-29
AU2003226731B2 (en)	2008-05-22
WO2003082872A1 (en)	2003-10-09
EP1348707A1 (de)	2003-10-01
JP2005527565A (ja)	2005-09-15
EP1348707B1 (de)	2010-08-25
US20050080097A1 (en)	2005-04-14

Legal Events

Date	Code	Title	Description
2011-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE478872T1 (de)	2010-09-15	Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
CA2184919A1 (en)	1996-07-18	New Piperazine Derivatives and Methods for the Preparation Thereof and Compositions Containing the Same
BG107120A (bg)	2003-05-30	Нови бавнодействащи бетамиметици, метод за тяхното получаване и приложението им като лекарствени средства
CA2337041A1 (en)	2000-02-17	Aminomethylcarboxylic acid derivatives
WO2003076458A3 (en)	2003-11-06	Selective dipeptide inhibitors of kallikrein
CA2368413A1 (en)	2000-10-05	Derivatives of pyrimido[6,1-a]isoquinolin-4-one
HUP0301671A2 (hu)	2003-08-28	4-Fenil-piridin-származékok, mint neurokinin-1-receptor antagonisták, eljárás az előállításukra és alkalmazásuk
DE69528437D1 (de)	2002-11-07	Substituierte azaindolylidenderivate und verfahren zu ihrer herstellung
WO2005092858A3 (en)	2006-03-02	Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
SE0104332D0 (sv)	2001-12-19	Therapeutic agents
MY141504A (en)	2010-05-14	Gamma secretase inhibitors
TW368501B (en)	1999-09-01	7-(2-aminoethyl)-benzothiazolones
TW235297B (de)	1994-12-01
DE3876813D1 (de)	1993-02-04	3(2h)pyridazinon, verfahren zu dessen herstellung und dieses enthaltendes mittel gegen srs-a.
EP2289888A3 (de)	2011-07-13	Epoxidcarboxylsäureamide, Azide und Aminoalkohole sowie Verfahren zur Herstellung von Alpha-Ketoamiden damit
MX9706394A (es)	1997-11-29	Compuestos de 1-aril-2-acilamino-etano y su uso como antagonistas de neuroquinina, especialmente neuroquinina-1.
MY138051A (en)	2009-04-30	Compounds and processes
TW200420559A (en)	2004-10-16	Amine compounds and method for producing the same
ES2191341T3 (es)	2003-09-01	Derivados de la 2-fenoxianilina.
AR023914A1 (es)	2002-09-04	Caprolactamas sustituidas, un proceso para su preparacion, composiciones farmaceuticas que las contienen, y su uso para la preparacion de composicionesfarmaceuticas en el tratamiento de tumores
EP0431520A3 (en)	1992-06-03	Heterocyclic acyl aminodiol beta-amino acid derivatives
DE50202381D1 (de)	2005-04-07	Geschützte tyrosinderivate, verfahren zu deren herstellung und deren verwendung zur herstellung von o-(2- ?18 f]-fluorethyl)-l-tyrosin
GB0113232D0 (en)	2001-07-25	Chemical process
MXPA01009768A (es)	2004-08-12	Analogos de fenoxazina utiles como inhibidores de la agregacion amiloide y para el tratamiento de la enfermedad de alzheimer y las enfermedades relacionadas con la amiloidosis.
TW200510300A (en)	2005-03-16	Amino alcohol compounds